Allele-selective Transcriptional Repression of Mutant HTT for the Treatment of Huntington's Disease

Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by a CAG trinucleotide expansion in the huntingtin gene (HTT), which codes for the pathologic mutant HTT (mHTT) protein. Since normal HTT is thought to be important for brain function, we engineered zinc finger protein transcription factors (ZFP-TFs) to target the pathogenic CAG repeat and selectively lower mHTT as a therapeutic strategy. Using patient-derived fibroblasts and neurons, we demonstrate that ZFP-TFs selectively repress >99% of HD-causing alleles over a wide dose range while preserving expression of >86% of normal alleles. Other CAG-containing genes are minimally affected, and virally delivered ZFP-TFs are active and well tolerated in HD neurons beyond 100 days in culture and for at least nine months in the mouse brain. Using three HD mouse models, we demonstrate improvements in a range of molecular, histopathological, electrophysiological and functional endpoints. Our findings support the continued development of an allele-selective ZFP-TF for the treatment of HD.

Citing Articles

Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington's disease and Prion diseases.

Mukherjee A, Biswas S, Roy I Acta Pharmacol Sin. 2025; .

PMID: 39890942 DOI: 10.1038/s41401-024-01455-w.

Progressive lung fibrosis: reprogramming a genetically vulnerable bronchoalveolar epithelium.

Bridges J, Vladar E, Kurche J, Krivoi A, Stancil I, Dobrinskikh E J Clin Invest. 2025; 135(1).

PMID: 39744946 PMC: 11684817. DOI: 10.1172/JCI183836.

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding.

Mathews E, Coffey S, Gartner A, Belgrad J, Bragg R, OReilly D bioRxiv. 2024; .

PMID: 39574582 PMC: 11580907. DOI: 10.1101/2024.11.04.619693.

Development of artificial transcription factors and their applications in cell reprograming, genetic screen, and disease treatment.

Sang Y, Xu L, Bao Z Mol Ther. 2024; 32(12):4208-4234.

PMID: 39473180 PMC: 11638881. DOI: 10.1016/j.ymthe.2024.10.029.

UBL3 Interacts with PolyQ-Expanded Huntingtin Fragments and Modifies Their Intracellular Sorting.

Oyama S, Zhang H, Ferdous R, Tomochika Y, Chen B, Jiang S Neurol Int. 2024; 16(6):1175-1188.

PMID: 39449505 PMC: 11503352. DOI: 10.3390/neurolint16060089.

References

Ross C, Tabrizi S . Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2010; 10(1):83-98. DOI: 10.1016/S1474-4422(10)70245-3. View

Bates G, Dorsey R, Gusella J, Hayden M, Kay C, Leavitt B . Huntington disease. Nat Rev Dis Primers. 2016; 1:15005. DOI: 10.1038/nrdp.2015.5. View

Zuccato C, Valenza M, Cattaneo E . Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010; 90(3):905-81. DOI: 10.1152/physrev.00041.2009. View

Yamamoto A, Lucas J, Hen R . Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 2000; 101(1):57-66. DOI: 10.1016/S0092-8674(00)80623-6. View

Boudreau R, McBride J, Martins I, Shen S, Xing Y, Carter B . Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther. 2009; 17(6):1053-63. PMC: 2835182. DOI: 10.1038/mt.2009.17. View

Harper S, Staber P, He X, Eliason S, Martins I, Mao Q . RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005; 102(16):5820-5. PMC: 556303. DOI: 10.1073/pnas.0501507102. View

Kordasiewicz H, Stanek L, Wancewicz E, Mazur C, McAlonis M, Pytel K . Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012; 74(6):1031-44. PMC: 3383626. DOI: 10.1016/j.neuron.2012.05.009. View

McBride J, Pitzer M, Boudreau R, Dufour B, Hobbs T, Ojeda S . Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther. 2011; 19(12):2152-62. PMC: 3242667. DOI: 10.1038/mt.2011.219. View

Stiles D, Zhang Z, Ge P, Nelson B, Grondin R, Ai Y . Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol. 2011; 233(1):463-71. DOI: 10.1016/j.expneurol.2011.11.020. View

10.

Duyao M, AUERBACH A, Ryan A, Persichetti F, Barnes G, McNeil S . Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 1995; 269(5222):407-10. DOI: 10.1126/science.7618107. View

11.

Nasir J, Floresco S, OKusky J, Diewert V, Richman J, Zeisler J . Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995; 81(5):811-23. DOI: 10.1016/0092-8674(95)90542-1. View

12.

Dragatsis I, Levine M, Zeitlin S . Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 2000; 26(3):300-6. DOI: 10.1038/81593. View

13.

Arteaga-Bracho E, Gulinello M, Winchester M, Pichamoorthy N, Petronglo J, Zambrano A . Postnatal and adult consequences of loss of huntingtin during development: Implications for Huntington's disease. Neurobiol Dis. 2016; 96:144-155. PMC: 5102778. DOI: 10.1016/j.nbd.2016.09.006. View

14.

Wang G, Liu X, Gaertig M, Li S, Li X . Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis. Proc Natl Acad Sci U S A. 2016; 113(12):3359-64. PMC: 4812735. DOI: 10.1073/pnas.1524575113. View

15.

Dietrich P, Johnson I, Alli S, Dragatsis I . Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis. PLoS Genet. 2017; 13(7):e1006846. PMC: 5536499. DOI: 10.1371/journal.pgen.1006846. View

16.

Lopes F, Barbosa M, Ameur A, Soares G, De Sa J, Dias A . Identification of novel genetic causes of Rett syndrome-like phenotypes. J Med Genet. 2016; 53(3):190-9. DOI: 10.1136/jmedgenet-2015-103568. View

17.

Monteys A, Wilson M, Boudreau R, Spengler R, Davidson B . Artificial miRNAs Targeting Mutant Huntingtin Show Preferential Silencing In Vitro and In Vivo. Mol Ther Nucleic Acids. 2015; 4:e234. DOI: 10.1038/mtna.2015.7. View

18.

Pfister E, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M . Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol. 2009; 19(9):774-8. PMC: 2746439. DOI: 10.1016/j.cub.2009.03.030. View

19.

Gagnon K, Pendergraff H, Deleavey G, Swayze E, Potier P, Randolph J . Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry. 2010; 49(47):10166-78. PMC: 2991413. DOI: 10.1021/bi101208k. View

20.

Yu D, Pendergraff H, Liu J, Kordasiewicz H, Cleveland D, Swayze E . Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell. 2012; 150(5):895-908. PMC: 3444165. DOI: 10.1016/j.cell.2012.08.002. View